Pioglitazone (Actos)

01/01/2018 - "In conclusion, pioglitazone was associated with improvement in depressive symptoms, an effect more marked in women and poorly explained by effects on glycaemia and insulin resistance. "
05/01/2006 - "Insulin sensitivity, as assessed by homeostasis model assessment (2.20 +/- 1.62 vs. 3.61 +/- 1.87, P = 0.01), or the change of insulin sensitivity index from baseline to study end (0.021 +/- 0.023 vs. -0.003 +/- 0.012 micromol x kg(-1) x min(-1) per pmol/l, P = 0.0001) and beta-cell function (57.42 +/- 49.86 vs. 21.78 +/- 18.54 mU/l per mmol/l, P = 0.0014) significantly improved in the pioglitazone group, with no change observed after placebo. "
01/01/2021 - "The results showed significant improvement in the insulin sensitivity of pioglitazone-treated mice as manifested by significant reduction in the insulin resistance index. "
12/01/2020 - "Our findings provide new insight into the mechanism by which pioglitazone may be beneficial in the treatment of insulin resistance."
01/01/2018 - "Pioglitazone was associated with a significantly greater insulin sensitivity in adipose tissue of patients with diabetes vs without diabetes (P < .001), but nonsignificant differences in responses in hepatic (P = .49) and skeletal muscle (P = .32) insulin sensitivity. "

01/01/2009 - "A recent trial indicated that treatment with pioglitazone is effective for patients with type 2 diabetes. "
01/01/2018 - "In a prospective study, we found pioglitazone to be effective in patients with and without type 2 diabetes. "
01/01/2013 - "Clinical data currently available indicate that pioglitazone is an effective and generally well-tolerated treatment option for use in patients with type 2 diabetes. "
01/01/2013 - "Pioglitazone is a PPARγ agonist that is widely used for the treatment of type 2 diabetes mellitus. "
09/01/2000 - "These data suggest pioglitazone to be effective in reducing UAE and urinary ET-1 concentrations in NIDDM patients with microalbuminuria."

01/01/2018 - "Our results showed that NAFLD was improved significantly by pioglitazone in a CAR deletion state. "
11/18/2022 - "Pioglitazone intake is effective in nonalcoholic steatohepatitis management."
04/01/2014 - "Pioglitazone (15 mg/day), which has been identified to be effective for nonalcoholic steatohepatitis, was then administered. "
07/01/2012 - "Pioglitazone is effective in nonalcoholic steatohepatitis (NASH), but the mechanisms of action are not completely understood. "
01/01/2019 - "Use of pioglitazone seemed to be protective against the development of NAFLD. "

12/01/2012 - "Patients treated with pioglitazone had significant improvement in lobular inflammation, portal inflammation and Brunts grade. "
04/01/2011 - "Pioglitazone is particularly effective for improving the manifestations of diabetic dyslipidaemia, in addition to its favorable effects on systemic inflammation and hyperglycaemia. "
05/13/2023 - "Where, the biochemical, hematological and histopathological investigations showed that the hepatotoxicity, renal inflammation, hematological disorders and histopathological changes were improved using combination of Actos and Artemisia extract. "
01/01/2023 - "Pioglitazone modulates immune activation and ameliorates inflammation induced by injured renal tubular epithelial cells via PPARγ/miRNA‑124/STAT3 signaling."
10/01/2021 - "The primary endpoint was the efficacy of pioglitazone in reducing inflammation and liver fat at end-of-treatment (EOT). "

08/01/2010 - "Pioglitazone (10, 20 and 40mg/kg, p.o.) treatment significantly improved body weight and motor functions, oxidative defense. "
11/01/2017 - "Pioglitazone (10mg/kg body weight/day) was used to compare the efficacy of PAAE. "
11/01/2014 - "In this study, we observed a reversal of body weight gain but no recoveries in red blood cells or haematocrit or haemoglobin levels after stopping pioglitazone for 10 months in patients treated with pioglitazone for 38 months. "
01/01/2005 - "Body weight and fat increased steadily in the patients treated with pioglitazone during the 6 months of the study (+3.9 +/- 3.1 kg at 6 months in pioglitazone-treated patients vs -0.8 +/- 3.4 kg in the placebo-treated patients). "
05/15/2022 - "Male, Wistar rats, 60 days age and 305 g body weight average were treated with vehicle, pioglitazone or GQ-11 (20 mg/kg) for 7 consecutive days and were submitted to aorta clamping for 30 min followed by 3 h of reperfusion. "